Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Norelgestromin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 8/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.74 |
| ▸ | LMNA | P02545 | 6/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.74 |
| ▸ | ESR1 | P03372 | 5/20 | 0.74 |
| ▸ | AR | P10275 | 5/20 | 0.74 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.74 |
| ▸ | SHBG | P04278 | 4/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.73 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.73 |
| ▸ | PDK3 | Q15120 | 3/20 | 0.73 |
| ▸ | PDK4 | Q16654 | 3/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norelgestromin SCHEMBL4814611 | 1.00 | NR1I2 (1.00) | NR1I2PGRSLC6A4LMNACYP3A4 | |
| Norelgestromin SCHEMBL3267125 | 1.00 | NR1I2 (1.00) | NR1I2PGRSLC6A4LMNACYP3A4 | |
| Norelgestromin SCHEMBL3163347 | 1.00 | NR1I2 (1.00) | NR1I2PGRSLC6A4LMNACYP3A4 | |
| Norelgestromin SCHEMBL4814600 | 1.00 | NR1I2 (1.00) | NR1I2PGRSLC6A4LMNACYP3A4 | |
| SCHEMBL14198630 | 0.89 | NR1I2 (0.80) | NR1I2PGRSLC6A4LMNACYP3A4 | |
| SCHEMBL13306245 | 0.88 | NR1I2 (0.78) | NR1I2PGRSLC6A4LMNACYP3A4 | |
| Norgestimate SCHEMBL7532415 | 0.85 | PGR (0.84) | NR1I2PGRSLC6A4LMNACYP3A4 | |
| Levonorgestrel SCHEMBL22364344 | 0.85 | PGR (1.00) | NR1I2PGRSLC6A4LMNACYP3A4 | |
| Levonorgestrel SCHEMBL27597 | 0.85 | PGR (1.00) | NR1I2PGRSLC6A4LMNACYP3A4 | |
| Levonorgestrel SCHEMBL21741985 | 0.85 | PGR (1.00) | NR1I2PGRSLC6A4LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2131 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053736-A1 | LONG ACTING DRUG DELIVERY DEVICE AND ITS USE IN CONTRACEPTION | BAYER OY (FI) | 2026-02-26 | — | — | US | claimed |
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) | 2025-11-06 | — | — | US | claimed |
| US-20250255968-A1 | INTRAVAGINAL DEVICES FOR DRUG DELIVERY | KISER PATRICK F (US) | 2025-08-14 | — | — | US | claimed |
| US-20250195450-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | HERA HEALTH SOLUTIONS INC. | 2025-06-19 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250152556-A1 | ETRASIMOD FOR USE IN TREATING S1P1 RECEPTOR-ASSOCIATED DISORDERS IN COMBINATION WITH HORMONE TREATMENT | ARENA PHARMACEUTICALS, INC. (US) | 2025-05-15 | — | — | US | claimed |
| US-20250000815-A1 | PATCH | MEDHERANT LTD (GB) | 2025-01-02 | — | — | US | claimed |
| US-20240358655-A1 | Transdermal Systems having low dose estrogen and methods of making and use | VIATRIS INC. (US) | 2024-10-31 | — | — | US | claimed |
| US-12128142-B2 | Patch | MEDHERANT LTD (GB) | 2024-10-29 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20050250747-A1 | Management of breakthrough bleeding in extended hormonal contraceptive regimens | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2005-11-10 | — | — | US | claimed |
| US-20050032763-A1 | Process for the synthesis of high purity D-(17a)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one oxime | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2005-02-10 | — | — | US | claimed |
| US-20050032764-A1 | Process of making isomers of norelgestromin and methods using the same | RICHTER GEDEON VEGYESZETI GYAR RT. | 2005-02-10 | — | — | US | claimed |
| WO-2005000868-A1 | PROCESS FOR THE SYNTHESIS OF HIGH PURITY D-(17ALPHA)-13-ETHYL-17HYDROXY-18,19-DINORPRE:GN-4-ENE-20-YNE-3-ONE-OXIME | RICHTER GEDEON VEGYÉSZETI GYÁR R.T. (HU) | 2005-01-06 | — | — | WO | claimed |
| US-20040266741-A1 | free of norgestimate, in which the main impurity is levonorgestrel that is the first metabolite of the norelgestromin | GADOR S.A. (AR) | 2004-12-30 | — | — | US | claimed |
| WO-2004080442-A1 | EXTENDED TRANSDERMAL CONTRACEPTIVE REGIMENS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-23 | — | — | WO | claimed |
| EP-1450772-A1 | MICRONIZED FILM-FORMING POWDER COMPRISING AN ACTIVE SUBSTANCE | Besins International Belgique (BE) | 2004-09-01 | — | — | EP | claimed |
| US-20040142914-A1 | Extended transdermal contraceptive regimens | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-22 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2003043612-A1 | MICRONIZED FILM-FORMING POWDER COMPRISING AN ACTIVE SUBSTANCE | BESINS INTERNATIONAL BELGIQUE (BE) | 2003-05-30 | — | — | WO | claimed |